Levalbuterol tartrate is a medication used to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD) [1]. It is also used for the prevention of exercise-induced bronchoconstriction [1]. The drug functions as a short-acting beta2-adrenergic agonist, which relaxes the smooth muscles in the airways, making breathing easier [1].
What forms does levalbuterol tartrate come in?
Levalbuterol tartrate is available in two primary forms: a nebulized solution and an inhalation aerosol [1]. The nebulized solution is typically administered using a nebulizer device, while the inhalation aerosol is used with an inhaler [1].
How does levalbuterol tartrate work?
As a beta2-adrenergic agonist, levalbuterol tartrate selectively targets beta2 receptors located in the smooth muscles of the lungs [1]. Activation of these receptors leads to the relaxation of these muscles, causing bronchodilation, or widening of the airways [1]. This effect helps to relieve symptoms such as wheezing and shortness of breath [1].
What is the difference between levalbuterol and albuterol?
Levalbuterol is the R-enantiomer of albuterol [2]. While albuterol is a racemic mixture containing both R- and S-enantiomers, levalbuterol is the pure R-enantiomer [2]. Studies suggest that the R-enantiomer is primarily responsible for the bronchodilator effects, while the S-enantiomer may be associated with some adverse effects [2]. This difference in enantiomeric composition is the basis for levalbuterol's development and marketing as a potentially improved alternative [2].
When does levalbuterol tartrate patent expire?
Patent expiry dates for medications can be complex and may vary depending on specific patents and any subsequent extensions or litigation. Information regarding the patent status of levalbuterol tartrate, including potential expiry dates for relevant patents, can be found on resources like DrugPatentWatch.com [3]. Understanding patent exclusivity is crucial for the development of generic alternatives [3].